Sino Biopharmaceutical Limited (SBHMY)
USD 8.34
(0.0%)
USD 8.34
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 26.19 Billion CNY | -8.97% |
| 2022 | 28.78 Billion CNY | 7.14% |
| 2021 | 26.86 Billion CNY | 13.59% |
| 2020 | 23.64 Billion CNY | -2.42% |
| 2019 | 24.23 Billion CNY | 16.02% |
| 2018 | 20.88 Billion CNY | 40.96% |
| 2017 | 14.81 Billion CNY | 4.58% |
| 2016 | 14.17 Billion CNY | 16.3% |
| 2015 | 12.18 Billion CNY | 23.09% |
| 2014 | 9.89 Billion CNY | 27.94% |
| 2013 | 7.73 Billion CNY | 15.4% |
| 2012 | 6.7 Billion CNY | 43.27% |
| 2011 | 4.67 Billion CNY | 34.39% |
| 2010 | 3.48 Billion CNY | 21.94% |
| 2009 | 2.85 Billion CNY | 42.12% |
| 2008 | 2 Billion CNY | 84.24% |
| 2007 | 1.09 Billion CNY | 48.06% |
| 2006 | 736.63 Million CNY | -6.4% |
| 2005 | 787.02 Million CNY | -29.67% |
| 2004 | 1.11 Billion CNY | 27.73% |
| 2003 | 876.11 Million CNY | 19.24% |
| 2002 | 734.72 Million CNY | 28.23% |
| 2001 | 572.97 Million CNY | 37.46% |
| 2000 | 416.84 Million CNY | 28.06% |
| 1999 | 325.51 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.19 Billion USD | 0.0% |
| 2023 Q1 | 7.63 Billion USD | 292.58% |
| 2023 FY | 26.19 Billion CNY | -8.97% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q4 | 1.5 Billion USD | 0.0% |
| 2023 Q2 | 2.2 Billion USD | -71.14% |
| 2022 Q4 | 1.94 Billion USD | -71.36% |
| 2022 Q1 | 7.59 Billion CNY | 21.48% |
| 2022 Q2 | 7.59 Billion CNY | 0.0% |
| 2022 FY | 28.78 Billion CNY | 7.14% |
| 2022 Q3 | 6.79 Billion USD | -10.58% |
| 2021 Q2 | 7.11 Billion CNY | -1.83% |
| 2021 Q4 | 6.25 Billion CNY | 0.0% |
| 2021 Q3 | 6.25 Billion CNY | -12.05% |
| 2021 FY | 26.86 Billion CNY | 13.59% |
| 2021 Q1 | 7.24 Billion CNY | 31.18% |
| 2020 Q3 | 5.47 Billion CNY | -14.75% |
| 2020 FY | 23.64 Billion CNY | -2.42% |
| 2020 Q1 | 6.22 Billion CNY | 26.63% |
| 2020 Q2 | 6.42 Billion CNY | 3.28% |
| 2020 Q4 | 5.52 Billion CNY | 0.79% |
| 2019 Q1 | 6.2 Billion CNY | 20.35% |
| 2019 FY | 24.23 Billion CNY | 16.02% |
| 2019 Q4 | 4.91 Billion CNY | -27.68% |
| 2019 Q3 | 6.79 Billion CNY | 7.5% |
| 2019 Q2 | 6.31 Billion CNY | 1.79% |
| 2018 FY | 20.88 Billion CNY | 40.96% |
| 2018 Q1 | 4.65 Billion CNY | 37.95% |
| 2018 Q2 | 5.07 Billion CNY | 9.03% |
| 2018 Q3 | 6 Billion CNY | 18.38% |
| 2018 Q4 | 5.15 Billion CNY | -14.1% |
| 2017 Q4 | 3.37 Billion CNY | -14.92% |
| 2017 Q3 | 3.96 Billion CNY | 9.51% |
| 2017 Q2 | 3.61 Billion CNY | -6.3% |
| 2017 Q1 | 3.86 Billion CNY | 8.24% |
| 2017 FY | 14.81 Billion CNY | 4.58% |
| 2016 Q3 | 3.72 Billion CNY | 9.47% |
| 2016 Q1 | 3.47 Billion CNY | 24.66% |
| 2016 Q4 | 3.56 Billion CNY | -4.15% |
| 2016 FY | 14.17 Billion CNY | 16.3% |
| 2016 Q2 | 3.4 Billion CNY | -2.12% |
| 2015 Q2 | 2.97 Billion CNY | -0.53% |
| 2015 FY | 12.18 Billion CNY | 23.09% |
| 2015 Q1 | 2.98 Billion CNY | 12.88% |
| 2015 Q4 | 2.78 Billion CNY | -18.79% |
| 2015 Q3 | 3.43 Billion CNY | 15.45% |
| 2014 Q4 | 2.64 Billion CNY | 5.73% |
| 2014 Q2 | 2.41 Billion CNY | 3.48% |
| 2014 Q1 | 2.33 Billion CNY | 24.32% |
| 2014 FY | 9.89 Billion CNY | 27.94% |
| 2014 Q3 | 2.5 Billion CNY | 3.79% |
| 2013 Q1 | 1.83 Billion CNY | 5.56% |
| 2013 Q2 | 1.93 Billion CNY | 5.55% |
| 2013 Q3 | 2.08 Billion CNY | 7.5% |
| 2013 Q4 | 1.87 Billion CNY | -10.02% |
| 2013 FY | 7.73 Billion CNY | 15.4% |
| 2012 Q1 | 1.45 Billion CNY | 31.01% |
| 2012 Q4 | 1.74 Billion CNY | -0.51% |
| 2012 Q3 | 1.74 Billion CNY | -0.58% |
| 2012 Q2 | 1.75 Billion CNY | 20.91% |
| 2012 FY | 6.7 Billion CNY | 43.27% |
| 2011 Q2 | 1.2 Billion CNY | 15.55% |
| 2011 Q1 | 1.04 Billion CNY | 0.0% |
| 2011 FY | 4.67 Billion CNY | 34.39% |
| 2011 Q3 | 1.31 Billion CNY | 9.24% |
| 2011 Q4 | 1.11 Billion CNY | -15.73% |
| 2010 Q2 | 886.75 Million CNY | 10.89% |
| 2010 Q1 | 799.64 Million CNY | 0.0% |
| 2010 FY | 3.48 Billion CNY | 21.94% |
| 2009 FY | 2.85 Billion CNY | 42.12% |
| 2008 FY | 2 Billion CNY | 84.24% |
| 2007 FY | 1.09 Billion CNY | 48.06% |
| 2006 FY | 736.63 Million CNY | -6.4% |
| 2005 FY | 787.02 Million CNY | -29.67% |
| 2004 FY | 1.11 Billion CNY | 27.73% |
| 2003 FY | 876.11 Million CNY | 19.24% |
| 2002 FY | 734.72 Million CNY | 28.23% |
| 2001 FY | 572.97 Million CNY | 37.46% |
| 2000 FY | 416.84 Million CNY | 28.06% |
| 1999 FY | 325.51 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -34131046.025% |
| CSL Limited | 14.69 Billion USD | -78.349% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -166002.891% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -148682772.709% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -143710.566% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -21208.332% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -443807.303% |
| Marizyme, Inc. | 645.81 Thousand USD | -4056729.253% |
| Genus plc | 668.8 Million USD | -3817.376% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -6387429.165% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -66297306.245% |
| MultiCell Technologies, Inc. | 49.32 USD | -53121267134.388% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -52592.844% |
| EV Biologics, Inc. | 48.9 Thousand USD | -53577423.517% |
| Q BioMed Inc. | 284.35 Thousand USD | -9213624.187% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -88420.489% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -37427627.143% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -121882.536% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -34598453.959% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -39860247.188% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -3978549.81% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -10579.861% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -26465553.474% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | -2036.432% |
| HST Global, Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -2622563363.463% |
| Enzolytics Inc. | 52.79 Thousand USD | -49623752.186% |
| Resverlogix Corp. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -4305295.67% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -1355977.07% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -17956.152% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -4697576.032% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -18681471.141% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4243516.453% |
| ONE Bio Corp. | 52.29 Million USD | -49998.109% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | -3020.727% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -2625812.224% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -54082.506% |
| BioStem Technologies, Inc. | 16.68 Million USD | -156919.917% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -11075064.44% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -11075064.44% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -1913662.527% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -5530351.734% |
| SYBLEU INC | 11.69 Thousand USD | -224003054.925% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -336264.219% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -201533815.385% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -66270474.695% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -786669.039% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -392989.407% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -2521498.556% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -101578.15% |
| CSL Limited | 14.8 Billion USD | -77.023% |
| Cellectis S.A. | 755 Thousand USD | -3470020.397% |